Skip to main content
. 2017 Nov 7;8(6):1265–1296. doi: 10.1007/s13300-017-0328-6

Fig. 2a–b.

Fig. 2a–b

Changes in HbA1c with Mix50 or low-mix insulin analog treatment in studies of initiation (a) or intensification (b). P values shown are comparisons between target groups, where reported. aChange from baseline calculated from baseline and end point values. bSubanalysis of Watada trial. CHO carbohydrate, HbA1c glycated hemoglobin, low-mix premixed insulin analog containing 25% or 30% rapid-acting component, LSM least-squares mean, Mix50 premixed insulin analog containing 50% rapid-acting component, ND not determined, NS not significant